Prevention of meningococcal serogroup C disease by NeisVac-C™

Abstract

NeisVac-C™ has been demonstrated to be safe, immunogenic and efficacious when administered to infants, toddlers, older children and adults. It is one of the licensed meningococcal serogroup C conjugate vaccines and a single dose in infancy may be sufficient for protection until a booster dose is given in the second year of life. Persistence of serum bactericidal antibody, rather than immune memory, is now known to be a more appropriate correlate of long-term protection for serogroup C meningococcal disease. NeisVac-C was demonstrated to enhance responses to Haemophilus influenzae type b (Hib) polyribosylribitol phosphate when coadministered with Hib–tetanus toxoid conjugate vaccines. NeisVac-C also enhances tetanus toxid responses and a dose of NeisVac-C in older children induces responses similar to a dose of tetanus toxoid vaccine.

Keywords::

• efficacy
• herd immunity
• immunogenicity
• meningococcal serogroup C conjugate vaccine
• NeisVac-C™
• reactogenicity

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Notes

^*Mutual Recognition Procedure countries.

Source: Baxter Pharmacovigilance.